VIICTR
Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (2)
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply.
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply.
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer - Authors' reply. Lancet Oncol. 2020 11; 21(11):e516.
View in:
PubMed
subject areas
Biliary Tract Neoplasms
Humans
Imidazoles
Oximes
Proto-Oncogene Proteins B-raf
Pyridones
Pyrimidinones
authors with profiles
VIVEK SUBBIAH